5. Culturally Competent Care for Substance Users Diagnosed with HIV Disease
References
Kapadia F, Vlahov D, Donahoe RM, Friedland G. The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations. Clin Infect Dis. 2005;41:1027-1034.
Madden JJ, Wang Y, Lankford-Turner P, Donahoe RM. Does reduced DNA repair capacity play a role in HIV infection and progression in the lymphocytes of opiate addicts? J Acquir Immune Defic Syndr. 2002;31:S78-S83.
Celentano DD, Lucas G. Optimizing treatment outcomes in HIV-infected patients with substance abuse issues. Clin Infect Dis. 2007;45:S318-S323.
Nijhawan A, Kim S, Rich JD. Management of HIV infection in patients with substance use problems. Curr Infect Dis Rep. 2008;10:432-438.
Wood E, Kerr T, Hogg R, et al. Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users. Drug Alcohol Rev. 2006;25:451-454.
Substance Abuse and Mental Health Services Administration. Results from the 2008 National Survey on Drug Use and Health: National Findings. Available at: http://www.oas.samhsa.gov/nsduh/2k8nsduh/2k8Results.cfm. Accessed February 15, 2012.
Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS One. 2009;4:e7558.
Volkow ND, Montaner J. Enhanced HIV testing, treatment, and support for HIV-infected substance users. JAMA. 2010;303:1423-1424.
Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368:531-536.
Wood E, Kerr T, Marshall B, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338:b1649.
Lert F, Kazatchkine MD. Antiretroviral HIV treatment and care for injecting drug users: an evidence based overview. Int J Drug Policy. 2007;18:255-261.
Wood E, Hogg RS, Lima VD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008;300:550-554.
Wood E, Hogg RS, Yip B, et al. Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use. AIDS. 2005;19:1189-1195.
Tuboi SH, Harrison LH, Sprinz E, Albernaz RK, Schechter M. Predictors of virologic failure in HIV-1–infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. J Acquir Immune Defic Syndr. 2005;40:324-328.
Knobel H, Guelar A, Carmona A, et al. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. AIDS Patient Care STDs. 2001;15:193-199.
Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377-381.
Wood E, Montaner JS, Yip B, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ. 2003;169:656-661.
Wood E, Montaner JS, Yip B, et al. Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users. Antivir Ther. 2004;9:229-235.
Gruber VA, McCance-Katz EF. Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Curr HIV/AIDS Rep. 2010;7:152-160.
McCance-Katz EF, Rainey PM, Friedland G, Kosten TR, Jatlow P. Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict. 2001;10:296-307.